Covered recipient · General Payments record
JOHN W KLEIN
Allopathic & Osteopathic Physicians Ophthalmology
General Payments · PY2018–2024
$5,307.15
- Reported across 138 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $397.88 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Alcon Laboratories Inc | $145.86 | 3 |
| ABBVIE INC. | $84.15 | 4 |
| Bausch & Lomb Americas Inc. | $37.10 | 2 |
| Harrow Eye, LLC | $25.44 | 1 |
| Amgen Inc. | $25.36 | 1 |
| Tarsus Pharmaceuticals, Inc. | $24.38 | 1 |
| Astellas Pharma US Inc | $22.47 | 1 |
| Ocular Therapeutix, Inc. | $18.16 | 1 |
| BIOTISSUE HOLDINGS INC. | $14.96 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $25.93 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104084242 | CMS |
| ABBVIE INC. | $19.61 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104084244 | CMS |
| ABBVIE INC. | $18.71 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104084246 | CMS |
| ABBVIE INC. | $19.90 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104084248 | CMS |
| Alcon Vision LLC | $27.67 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110585151 | CMS |
| Alcon Vision LLC | $91.53 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110585153 | CMS |
| Alcon Vision LLC | $26.66 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110585149 | CMS |
| Amgen Inc. | $25.36 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111621326 | CMS |
| Astellas Pharma US Inc | $22.47 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139451328 | CMS |
| Bausch & Lomb Americas Inc. | $18.47 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140371847 | CMS |
| Bausch & Lomb Americas Inc. | $18.63 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140371849 | CMS |
| BIOTISSUE HOLDINGS INC. | $14.96 | 09/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148755658 | CMS |
| Harrow Eye, LLC | $25.44 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145606798 | CMS |
| Ocular Therapeutix, Inc. | $18.16 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148199823 | CMS |
| Tarsus Pharmaceuticals, Inc. | $24.38 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139108547 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.